Orange Book product · Generic (ANDA)
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
At a glance
Mar 04, 2026
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Mar 04, 2026
4 mo ago
Today
Pharmaceutical detail
Active ingredient
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
Strength
200MG;EQ 25MG BASE;300MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 220232
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
